Mind Medicine (MNMD) announced that it will be added to the Nasdaq Biotechnology Index NBI , effective at market open on Monday, December 23. “2024 has been a transformational year for MindMed.
Fintel reports that on December 20, 2024, Chardan Capital initiated coverage of Mind Medicine (NasdaqGS:MNMD) with a Buy recommendation. As of December 3, 2024, the average one-year price target ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Mind Medicine (MindMed) Stock Performance Mind Medicine (MindMed) stock opened at $7.16 on Friday. The company has a 50 day moving average price of $7.15 and a 200-day moving average price of $6. ...
NEW YORK, December 19, 2024--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain ...
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), with a market capitalization of $525 million, is a clinical-stage biopharmaceutical company at the forefront of developing innovative therapies for ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...